The translational data provide mechanistic support for pelareorep in hematological cancers but lack clinical response rates or survival data. Watch for the full ASH presentation on December 12, 2026 and any subsequent partnership or development updates.
Drug in focus
ONCY drug pipeline →pelareorep
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2/3
- Time to market
- At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
- Next catalyst
- None dated
What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $0.4077entry
- T+1 · 7d ago −6.35%α −5.98% · $0.3818
- T+5 · 20h ago −16.63%α −14.94% · $0.3399
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Oncolytics Biotech issued a press release announcing translational data from a Phase 1b/2 trial of pelareorep in relapsed/refractory multiple myeloma, to be presented at the ASH annual meeting. The data show pelareorep's ability to remodel the tumor microenvironment and activate immune responses, but no financial figures, clinical efficacy results, or regulatory milestones were disclosed.
Key Facts
- Translational data from a Phase 1b/2 trial in relapsed/refractory multiple myeloma patients with a median of four prior lines of therapy
- Data show increased CD8 effector memory T cells, enhanced antigen-presenting activity, and direct biological effects on tumor cells
- Presentation scheduled for December 12, 2026 at the 68th ASH Annual Meeting (poster #2183)
- No clinical efficacy results, financial figures, or regulatory updates were provided
Financial Impact
No financial impact disclosed; the filing is a routine data announcement with no revenue, cost, or capital implications
Risk Factors
- Early-stage translational data may not translate to clinical efficacy
- No financial or regulatory catalysts announced
- Company has a small market cap ($59M) and may face capital constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000080 |
| Document: oncyash2026.htm | 0001129928-26-000080 |
| Document: 0001129928-26-000080-index-headers.html | 0001129928-26-000080 |
| Document: 0001129928-26-000080-index.html | 0001129928-26-000080 |
| Document: 0001129928-26-000080.txt | 0001129928-26-000080 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Viewing Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers